Dynamic changes in circulating microRNAs during oral glucose tolerance testing support their potential as diagnostic and monitoring biomarkers in cystic fibrosis-related diabetes
MiR-34a-5p and miR-122-5p show potential as biomarkers for CFRD development and liver damage. MiR-122-5p and miR-223-3p could mitigate CFRD development by increasing the secretory capacity of the beta cells while miR-34a-5p might propagate CFRD development by reducing cell viability. We propose that circulating microRNAs can serve as biomarkers for CF complications. We further advocate that circulating microRNAs can play a part in the intricate crosstalk between metabolic organs and the endocrine pancreas in health and disease.
Authors
- Alexandros Karagiannopoulos (ORCID: https://orcid.org/0000-0001-8458-1065)
- Anna Wendt (ORCID: https://orcid.org/0000-0001-8807-5979)
- Bibi U Nielsen
- Lena Eliasson (ORCID: https://orcid.org/0000-0002-6467-5029)
- Efraim Westholm (ORCID: https://orcid.org/0000-0002-2383-8549)
- Faurholt-Jepsen Daniel
- James A. M. Shaw
Institutions
- University of Copenhagen (DK)
- Malmö University (SE)
- Lund University (SE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Skåne University Hospital (SE)
- Newcastle University (GB)
Publication Details
- Journal
- Diabetologia
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1007/s00125-025-06645-7
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cystic Fibrosis Trust
- Stiftelsen för Strategisk Forskning
- Lunds Universitet
- Vetenskapsrådet
- Barndiabetesfonden
- Rigshospitalet
- Kungliga Fysiografiska Sällskapet i Lund
- Direktör Albert Påhlssons Stiftelse
- Stiftelsen Riksförbundet Cystisk Fibros Forskningsfond